Amyotrophic Lateral Sclerosis (ALS) Research
Developing innovative combination therapies targeting multiple pathways to halt motor neuron degeneration in ALS
Updated on January 12, 2025
Research Overview
Amyotrophic Lateral Sclerosis (ALS) is a complex neurodegenerative disease affecting motor neurons in the brain and spinal cord. Our research focuses on developing combination therapy approaches that simultaneously target multiple pathological pathways, recognizing that ALS requires multi-modal therapeutic interventions for effective treatment.
We integrate gene therapy, neuroprotective compounds, and anti-inflammatory strategies into synergistic combination treatments. Using CRISPR tools, advanced imaging, and computational modeling, we design personalized therapeutic cocktails tailored to individual ALS genetic profiles and disease stages.
Research Approaches
Multi-Target Combination Therapy
Designing therapeutic combinations that simultaneously address protein aggregation, neuroinflammation, and mitochondrial dysfunction
Synergistic Gene Therapy
Combining AAV-delivered neuroprotective factors with CRISPR-based gene correction for enhanced therapeutic efficacy
Personalized Treatment Cocktails
Using AI to optimize drug combinations based on individual genetic profiles and disease progression patterns
Key Research Areas
Multi-Pathway Targeting
Simultaneously targeting genetic, inflammatory, and metabolic pathways in ALS pathogenesis
Therapeutic Synergy
Combining gene therapy, small molecules, and biologics for enhanced therapeutic outcomes
AI-Driven Optimization
Using machine learning to optimize combination therapy dosing and timing protocols
Current Research Projects
Integrated Combination Therapy Platform for ALS
We are developing a comprehensive combination therapy platform that integrates multiple therapeutic modalities to address the complex pathophysiology of ALS. This approach combines CRISPR-based gene correction, AAV-delivered neuroprotective factors, anti-inflammatory compounds, and metabolic enhancers into synergistic treatment protocols.
Our platform utilizes computational modeling to predict optimal drug combinations and dosing schedules for individual patients based on their genetic profiles, disease stage, and biomarker signatures. This personalized combination therapy approach aims to maximize therapeutic efficacy while minimizing adverse effects.
Multi-institutional collaboration • Translational research initiative